Opendata, web and dolomites

MOLEC ANTI-ARRHYT SIGNED

Resilience and Trigger Factors in Cardiac Arrhythmia: Risk Stratification and Drug Design

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MOLEC ANTI-ARRHYT project word cloud

Explore the words cloud of the MOLEC ANTI-ARRHYT project. It provides you a very rough idea of what is the project "MOLEC ANTI-ARRHYT" about.

potassium    unpublished    mutations    ranging    risk    personalized    ion    mutation    mechanisms    phenotypes    prototype    depending    diverse    qt    severity    despite    up    arrhythmia    resilience    arrhythmic    unexplored    individuals    hurdle    stratification    completion    variant    asymptomatic    spectrum    front    death    pathological    utilizes    arrhythmias    classes    interact    genotype    determined    computational    mechanism    effect    experimental    cardiac    channels    manifestations    lethal    paradoxically    arrhyt    harbour    avenues    inherited    trigger    utilize    therapeutic    correlation    syndrome    mutated    poor    outcome    display    manifestation    underlying    30    successful    fundamentally    genetic    40    line    mimetic    proof    alter    sudden    anti    ligands    linked    lifelong    causative    observations    positive    infancy    molec    protected    ultimately    treatment    drug    iks    endogenous    channel    clinical   

Project "MOLEC ANTI-ARRHYT" data sheet

The following table provides information about the project.

Coordinator
LINKOPINGS UNIVERSITET 

Organization address
address: CAMPUS VALLA
city: LINKOPING
postcode: 581 83
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Total cost 1˙499˙998 €
 EC max contribution 1˙499˙998 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2019-STG
 Funding Scheme ERC-STG
 Starting year 2020
 Duration (year-month-day) from 2020-03-01   to  2025-02-28

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    LINKOPINGS UNIVERSITET SE (LINKOPING) coordinator 1˙499˙998.00

Map

 Project objective

Up to 30% of individuals with inherited cardiac arrhythmias such as Long QT syndrome are not protected from sudden cardiac death despite state-of-the-art treatment. A major hurdle for effective risk stratification and treatment of inherited cardiac arrhythmias is the poor correlation between genetic variant and clinical manifestations. Affected individuals, who harbour the same arrhythmia-causative mutation, paradoxically display a spectrum of clinical phenotypes ranging from a lifelong asymptomatic state to sudden death in infancy. Up to 40% of genotype-positive individuals, depending on type of arrhythmia, do not display clinical manifestation. Based on our unpublished observations, I propose that an important, yet unexplored, underlying cause of the diverse clinical manifestations are endogenous resilience and trigger factors, which interact with mutated cardiac ion channels to alter arrhythmia severity. MOLEC ANTI-ARRHYT utilizes front-line experimental and computational approaches and the cardiac IKs potassium channel, which is strongly linked to lethal arrhythmias and sudden cardiac death, as a prototype. We aim to: (i) identify major classes of endogenous ligands with therapeutic (resilience factors) or pathological (trigger factors) effects on the IKs channel, (ii) provide proof of mechanism for how the effect of resilience and trigger factors is determined by arrhythmia-causative mutations in the IKs channel, (iii) utilize resilience mechanisms to develop a fundamentally novel concept of anti-arrhythmic drug development: Resilience-Mimetic Drug Development. The successful completion of this project will open up new avenues for personalized risk stratification and clinical management, which ultimately will improve the clinical outcome for individuals with inherited arrhythmias.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MOLEC ANTI-ARRHYT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MOLEC ANTI-ARRHYT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

evolSingleCellGRN (2019)

Constraint, Adaptation, and Heterogeneity: Genomic and single-cell approaches to understanding the evolution of developmental gene regulatory networks

Read More  

IMMUNOTHROMBOSIS (2019)

Cross-talk between platelets and immunity - implications for host homeostasis and defense

Read More  

RODRESET (2019)

Development of novel optogenetic approaches for improving vision in macular degeneration

Read More